The Science Behind Lantern Pharma
Lantern’s innovation and scientific drug development processes are reflected in numerous publications.
Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer
Masuda N., Negoro S., Hausheer F., Nakagawa K., Matsui K., Kudoh S., Takeda K., Yamamoto N., Yoshimura N., Ohashi Y., Fukuoka M.
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule
Boven E., Westerman M., van Groeningen C.J., Verschraagen M., Ruijter R., Zegers I., van der Vijgh W.J.F., Giaccone G.
Cysteine specific targeting of the functionally distinct peroxiredoxin and glutaredoxin proteins by the investigational disulfide BNP7787
Parker A.R., Petluru P.N., Nienaber V.L., Badger J., Leverett B.D., Jair K., Sridhar V., Logan C., Ayala P.Y., Kochat H., Hausheer F.H.
Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787
Parker A.R., Petluru P.N., Nienaber V.L., Zhao M., Ayala P.Y., Badger J., Chie-Leon B., Sridhar V., Logan C., Kochat H., Hausheer F.H.
Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo
Van Laar E.S., Roth S., Weitman S., MacDonald J.R., Waters S.J.
Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft
Kelner M.J., McMorris T.C., Estes L., Samson K.M., Bagnell R.D., Taetle R.
https://www.ejcancer.com/article/S0959-8049(98)00033-1/fulltext
Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents
Kelner M.J., McMorris T.C., Estes L., Wang W., Samson K.M., Taetle R.
Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor
Van Midwoud P.M., Sturla S.J.
Efficacy of acylfulvene illudili analogues against a metastatic lung carcinoma MV 522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC 2 and ERCC 3 DNA helicase-deficient cells
Kelner M.J., Mcmorris T.C., Estes L.A., Starr R.J., Rutherford M., Montoya M., Samson K.M., Taetle R.
Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways
Jaspers N.G., Raams A., Kelner M.J., Ng J.M., Yamashita Y.M., Takeda S., McMorris T.C., Hoeijmakers J.H.
Hydroxyurea derivatives of irofulven with improved antitumor efficacy
Staake M.D., Kashinatham A., McMorris T.C., Estes L.A., Kelner M.J.
Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents
Kelner M.J., McMorris T.C., Estes L., Rutherford M., Montoya M., Goldstein J., Samson K., Starr R., Taetle R.
Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent
Herzig M.C., Trevino A.V., Liang H., Salinas R., Waters S.J., MacDonald J.R., Woynarowska B.A., Woynarowski J.M.
Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent
Yu X., Erzinger M.M., Pietsch K.E., Cervoni-Curet F.N., Whang J., Niederhuber J., Sturla S.J.
Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells
Escargueil A.E., Poindessous V., Soares D.G., Sarasin A., Cook P.R., Larsen A.K.
Enantioselective total synthesis of (−)-Acylfulvene and (−)- Irofulven
Siegel D.S., Piizzi G., Piersanti G., Movassaghi M.
Let’s start a conversation about the future of cancer drug development.
We are a biotech pharma at the intersection of Artificial Intelligence, genomics, and oncology drug development.